My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AngioDynamics, Inc. - Common Stock (NQ:ANGO)

11.13 +0.13 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AngioDynamics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Nasdaq Moves Lower; Levi Strauss Shares Slide
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Crude Oil Jumps Over 4%; US Services PMI Revised Lower
 
Via Benzinga
Why AngioDynamics Stock Is Crashing Today
Investors didn't like the medical technology company's fiscal 2025 Q1 update. 
Via The Motley Fool
AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday
 
Via Benzinga
US Stocks Staring At Another Weak Open As Traders Await Key Jobs Report; Sentiment Wavers As Oil Extends Surge Amid Middle East Tensions
Sentiment continues to be cautious as traders play the “wait-and-watch” game until they see off Friday’s non-farm payroll data. The index futures traded moderately lower early Thursday. 
Via Benzinga
AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results
From AngioDynamics, Inc.
Via Business Wire
Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings
 
Via Benzinga
S&P Settles Slightly Higher Despite Middle East Concerns: Fear Index Remains In 'Greed' Zone
 
Via Benzinga
Topics Stocks
Constellation Brands, Levi Strauss And 3 Stocks To Watch Heading Into Thursday
 
Via Benzinga
AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for the Auryon System
From AngioDynamics, Inc.
Via Business Wire
PDD Holdings, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
AngioDynamics to Participate in Upcoming Investor Conferences
From AngioDynamics, Inc.
Via Business Wire
Nasdaq Edges Lower; Morgan Stanley Earnings Top Views
 
Via Benzinga
Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
AngioDynamics reported a Q4 2024 adjusted EPS loss of $(0.05), beating the consensus of $(0.16). Sales rose 1.9% to $79.1 million, driven by strong performance in the Med Tech segment. The company... 
Via Benzinga
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Crude Oil Down 1%; Bank of America Posts Upbeat Earnings
 
Via Benzinga
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
ANGO Stock Earnings: AngioDynamics Beats EPS, Beats Revenue for Q4 2024
ANGO stock results show that AngioDynamics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Fourth Quarter and Full-Year Financial Results
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics to Report Fiscal 2024 Fourth Quarter and Full-Year Financial Results on July 16, 2024
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System
From AngioDynamics, Inc.
Via Business Wire
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions
From AngioDynamics, Inc.
Via Business Wire
Insiders Buying Zumiez And 3 Other Stocks
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. 
Via Benzinga
Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars
FDA grants 510(k) clearance to AngioDynamics' AlphaVac F1885 System for pulmonary embolism. Expanded indication broadens treatment options. Sales slightly below consensus, but pro forma basis sees... 
Via Benzinga
ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024
ANGO stock results show that AngioDynamics missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
We're diving into the biggest pre-market stock movers that traders are going to want to keep an eye on for Thursday morning! 
Via InvestorPlace
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture
From AngioDynamics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.